跳至主要内容
临床试验/NL-OMON38190
NL-OMON38190
已完成
3 期

Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer - Cachexia (NSCLC-C): An Extension Study;(ROMANA-3) - Helsinn HT-ANAM-303 extension study (ROMANA 3)

Helsinn Therapeutics (U.S.), Inc0 个研究点目标入组 1 人待定

概览

阶段
3 期
干预措施
未指定
疾病 / 适应症
cachexie
发起方
Helsinn Therapeutics (U.S.), Inc
入组人数
1
状态
已完成
最后更新
去年

概览

简要总结

Trial is onging in other countries

注册库
who.int
开始日期
待定
结束日期
2013年10月15日
最后更新
去年
研究类型
Interventional

研究者

入排标准

入选标准

  • The patient has completed the Day 85 Visit in the original trial (Study HT ANAM\-301 or HT\-ANAM\-302\) and the Investigator considers the patient to be appropriate to continue to receive an additional 12 weeks of study drug administration. The patient must start dosing on the extension study within 5 days of completing dosing on the original trial.;• Females and males at least 18 years of age;• ECOG performance status less than / equal to 2

排除标准

  • Women who are pregnant or breast\-feeding;• Had major surgery (central venous access placement and tumor biopsies are not considered major surgery) within 4 weeks prior to enrollment into the extension study. Patients must be well recovered from acute effects of surgery prior to screening. Patients should not have plans to undergo major surgical procedures during the treatment period.;• Patients unable to readily swallow oral tablets. Patients with severe gastointestinal disease (including esophagitis, gastritis, malaborption, or obstructive symptoms) or intractable or frequent vomiting are excluded.;• Has known or symptomatic brain metastases

结局指标

主要结局

未指定

相似试验